PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 294, Issue 5, 2008, Pages

  Milam, Jami E ^a   Keshamouni, Venkateshwar G ^a   Phan, Sem H ^a   Hu, Biao ^a   Gangireddy, Srinivasa R ^a   Hogaboam, Cory M ^a   Standiford, Theodore J ^a   Thannickal, Victor J ^a   Reddy, Raju C ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Ciglitazone; Transforming growth factor; Troglitazone

Indexed keywords

BLEOMYCIN; CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TRANSFORMING GROWTH FACTOR BETA1; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CHROMAN DERIVATIVE; CYCLIN D; CYCLINE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; INFLAMMATION; INTERSTITIAL PNEUMONIA; LUNG FIBROBLAST; LUNG FIBROSIS; METABOLISM; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CELL CULTURE; CELL DIVISION; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; FIBROBLAST; FIBROSIS; FISCHER 344 RAT; GENE EXPRESSION; GENETICS; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; PROMOTER REGION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; CHROMANS; CYCLINS; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; PHENOTYPE; PPAR GAMMA; PROMOTER REGIONS (GENETICS); PULMONARY FIBROSIS; RATS; RATS, INBRED F344; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 45849149234     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00333.2007     Document Type: Article

References (73)

1. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3: 357-363, 2006.
2. Altiok S, Xu M, Spiegelman BM. PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 11: 1987-1998, 1997.
3. Antoniou KM, Pataka A, Bouros D, Siafakas NM. Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 20: 453-461, 2007.
4. August A, Mueller C, Weaver V, Polanco TA, Walsh ER, Cantorna MT. Nutrients, nuclear receptors, inflammation, immunity lipids, PPAR, and allergic asthma. J Nutr 136: 695-699, 2006.
5. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 53: 409-435, 2002.
6. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, Phipps RP, Sime PJ. PPARγ agonists inhibit TGF-β-induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 288: L1146-L1153, 2005.
7. Chana RS, Lewington AJ, Brunskill NJ. Differential effects of peroxisome proliferator-activated receptor-γ (PPARγ) ligands in proximal tubular cells: thiazolidinediones are partial PPARγ agonists. Kidney Int 65: 2081-2090, 2004.
8. Chittiboyina AG, Venkatraman MS, Mizuno CS, Desai PV, Patny A, Benson SC, Ho CI, Kurtz TW, Pershadsingh HA, Avery MA. Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARγ agonists. J Med Chem 49: 4072-4084, 2006.
9. Cho DH, Choi YJ, Jo SA, Ryou J, Kim JY, Chung J, Jo I. Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition. Am J Physiol Cell Physiol 291: C317-C326, 2006.
10. Clark JG, Madtes DK, Raghu G. Effects of platelet-derived growth factor isoforms on human lung fibroblast proliferation and procollagen gene expression. Exp Lung Res 19: 327-344, 1993.
11. Davies GF, McFie PJ, Khandelwal RL, Roesler WJ. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-γ expression in hepatocytes. J Pharmacol Exp Ther 300: 72-77, 2002.
12. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131: 281-303, 1999.
13. Del Peso G, Jimenez-Heffernan JA, Bajo MA, Hevia C, Aguilera A, Castro MJ, Sanchez-Tomero JA, Lopez-Cabrera M, Selgas R. Myo-fibroblastic differentiation in simple peritoneal sclerosis. Int J Artif Organs 28: 135-140, 2005.
14. Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA, Alison MR. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126: 955-963, 2004.
15. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122: 1924-1940, 2002.
16. 2 on bleomycin-induced lung injury. Eur Respir J 25: 225-234, 2005.
17. Gharaee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des 11: 3943-3971, 2005.
18. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor-β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor-γ. Arthritis Rheum 50: 1305-1318, 2004.
19. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 345: 517-525, 2001.
20. Grubstein A, Bendayan D, Schactman I, Cohen M, Shitrit D, Kramer MR. Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature. Respir Med 99: 948-954, 2005.
21. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells. Diabetes 53: 200-208, 2004.
22. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways. Mol Cancer Ther 5: 430-437, 2006.
23. He G, Thuillier P, Fischer SM. Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARγ in normal mouse skin keratinocytes. J Invest Dermatol 123: 1110-1119, 2004.
24. Honda K, Marquillies P, Capron M, Dombrowicz D. Peroxisome proliferator-activated receptor-γ is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol 113: 882-888, 2004.
25. Horton MR. Rheumatoid arthritis associated interstitial lung disease. Crit Rev Comput Tomogr 45: 429-440, 2004.
26. Hu B, Wu Z, Jin H, Hashimoto N, Liu T, Phan SH. CCAAT/enhancer-binding protein-β isoforms and the regulation of α-smooth muscle actin gene expression by IL-1β. J Immunol 173: 4661-4668, 2004.
27. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, Glass CK. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400: 378-382, 1999.
28. Huang TH, Razmovski-Naumovski V, Kota BP, Lin DS, Roufogalis BD. The pathophysiological function of peroxisome proliferator-activated receptor-γ in lung-related diseases. Respir Res 6: 102, 2005.
29. Jindal SK, Agarwal R. Autoimmunity and interstitial lung disease. Curr Opin Pulm Med 11: 438-446, 2005.
30. Keane MP, Lynch JP 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 55: 159-166, 2000.
31. Keane MP, Strieter RM, Belperio JA. Mechanisms and mediators of pulmonary fibrosis. Crit Rev Immunol 25: 429-463, 2005.
32. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23: 100-108, 2004.
33. Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei Y, Sato N. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 291: 55-61, 2002.
34. Lee HK, Kim DS, Yoo B, Seo JB, Rho JY, Colby TV, Kitaichi M. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 127: 2019-2027, 2005.
35. Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochem Biophys Res Commun 346: 83-88, 2006.
36. Lemay DG, Hwang DH. Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. J Lipid Res 47: 1583-1587, 2006.
37. Lu IL, Huang CF, Peng YH, Lin YT, Hsieh HP, Chen CT, Lien TW, Lee HJ, Mahindroo N, Prakash E, Yueh A, Chen HY, Goparaju CM, Chen X, Liao CC, Chao YS, Hsu JT, Wu SY. Structure-based drug design of a novel family of PPARγ partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. J Med Chem 49: 2703-2712, 2006.
38. Marzouk K, Corate L, Saleh S, Sharma OP. Epstein-Barr-virus- induced interstitial lung disease. Curr Opin Pulm Med 11: 456-460, 2005.
39. Masamune A, Kikuta K, Satoh M, Sakai Y, Satoh A, Shimosegawa T. Ligands of peroxisome proliferator-activated receptor-γ block activation of pancreatic stellate cells. J Biol Chem 277: 141-147, 2002.
40. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63: 5-24, 2005.
41. Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest 116: 598-606, 2006.
42. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, Anania FA, Willson TM, Tsukamoto H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275: 35715-35722, 2000.
43. Miyake Y, Sasaki S, Yokoyama T, Chida K, Azuma A, Suda T, Kudoh S, Sakamoto N, Okamoto K, Kobashi G, Washio M, Inaba Y, Tanaka H. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg 49: 259-265, 2005.
44. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. In press.
45. Nunes H, Soler P, Valeyre D. Pulmonary sarcoidosis. Allergy 60: 565-582, 2005.
46. Panchapakesan U, Sumual S, Pollock CA, Chen X. PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 289: F1153-F1158, 2005.
47. Peng Y, Liu H, Liu F, Liu Y, Li J, Chen X. Troglitazone inhibits synthesis of transforming growth factor-β1 and reduces matrix production in human peritoneal mesothelial cells. Nephrology (Carlton) 11: 516-523, 2006.
48. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 122: 286S-289S, 2002.
49. Poleni PE, Bianchi A, Etienne S, Koufany M, Sebillaud S, Netter P, Terlain B, Jouzeau JY. Agonists of peroxisome proliferator-activated receptors (PPAR) α, β/δ or γ reduce transforming growth factor (TGF)-β-induced proteoglycan production in chondrocytes. Osteoarthritis Cartilage 15: 493-505, 2007.
50. Raghu G, Chen YY, Rusch V, Rabinovitch PS. Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. Am Rev Respir Dis 138: 703-708, 1988.
51. Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7: R1113-R1123, 2005.
52. Ray DM, Akbiyik F, Bernstein SH, Phipps RP. CD40 engagement prevents peroxisome proliferator-activated receptor-γ agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-κB-dependent mechanism. J Immunol 174: 4060-4069, 2005.
53. Reddy RC, Keshamouni VG, Jaigirdar SH, Zeng X, Leff T, Thannickal VJ, Standiford TJ. Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor-γ ligands. Am J Physiol Lung Cell Mol Physiol 286: L613-L619, 2004.
54. Rizzo G, Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol 6: 421-427, 2006.
55. Routh RE, Johnson JH, McCarthy KJ. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 61: 1365-1376, 2002.
56. Saika S, Yamanaka O, Okada Y, Miyamoto T, Kitano A, Flanders KC, Ohnishi Y, Nakajima Y, Kao WW, Ikeda K. Effect of overexpression of PPARγ on the healing process of corneal alkali burn in mice. Am J Physiol Cell Physiol 293: C75-C86, 2007.
57. Schissel SL, Layne MD. Telomerase, myofibroblasts, and pulmonary fibrosis. Am J Respir Cell Mol Biol 34: 520-522, 2006.
58. Setoguchi Y, Ikeda T, Fukuchi Y. Clinical features and genetic analysis of surfactant protein C in adult-onset familial interstitial pneumonia. Respirology 11 Suppl: S41-S45, 2006.
59. Sheu SH, Kaya T, Waxman DJ, Vajda S. Exploring the binding site structure of the PPARγ ligand-binding domain by computational solvent mapping. Biochemistry 44: 1193-1209, 2005.
60. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, Chen CS. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ. Cancer Res 65: 1561-1569, 2005.
61. Standiford TJ, Keshamouni VG, Reddy RC. Peroxisome proliferatoractivated receptor-γ as a regulator of lung inflammation and repair. Proc Am Thorac Soc 2: 226-231, 2005.
62. Thannickal VJ, Flaherty KR, Martinez FJ, Lynch JP 3rd. Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin Pharmacother 5: 1671-1686, 2004.
63. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, Chacon R, Horowitz JC, Day RM, Thomas PE. Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 278: 12384-12389, 2003.
64. Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med 55: 395-417, 2004.
65. Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 66: 1281-1293, 2006.
66. Van Westerloo DJ, Florquin S, de Boer AM, Daalhuisen J, de Vos AF, Bruno MJ, van der Poll T. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol 166: 721-728, 2005.
67. 2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms. Br J Pharmacol 141: 517-525, 2004.
68. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 338: 916-917, 1998.
69. Weigert C, Brodbeck K, Bierhaus A, Haring HU, Schleicher ED. c-Fos-driven transcriptional activation of transforming growth factor-β-1: inhibition of high glucose-induced promoter activity by thiazolidinediones. Biochem Biophys Res Commun 304: 301-307, 2003.
70. Weissgarten J, Berman S, Efrati S, Rapoport M, Averbukh Z, Feldman L. Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats. Nephrol Dial Transplant 21: 1198-1204, 2006.
71. Willis BC, duBois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 3: 377-382, 2006.
72. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 350: 385-391, 2006.
73. Zheng F, Fornoni A, Elliot SJ, Guan Y, Breyer MD, Striker LJ, Striker GE. Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation. Am J Physiol Renal Physiol 282: F639-F648, 2002.